Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Profitability
This table compares Lexicon Pharmaceuticals and CorMedix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lexicon Pharmaceuticals | -4,109.41% | -107.38% | -64.09% |
| CorMedix | N/A | -79.21% | -64.68% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Lexicon Pharmaceuticals and CorMedix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lexicon Pharmaceuticals | 0 | 3 | 2 | 0 | 2.40 |
| CorMedix | 0 | 0 | 7 | 1 | 3.13 |
Insider and Institutional Ownership
74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Lexicon Pharmaceuticals and CorMedix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lexicon Pharmaceuticals | $31.08 million | 3.04 | -$177.12 million | ($0.64) | -0.60 |
| CorMedix | $12.26 million | 51.81 | -$46.34 million | ($0.81) | -12.93 |
CorMedix has lower revenue, but higher earnings than Lexicon Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Lexicon Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.
Summary
CorMedix beats Lexicon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
